Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lung Neoplasms × pyrotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 8 HER2-positive Breast Cancer 6 Carcinoma, Non-Small-Cell Lung 2 Salivary Gland Neoplasms 1 Rare Tumor 1 Pathologic Complete Response 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2 Positive Breast Cancer 1 HER2 Insertion Mutation Positive Advanced NSCLC 1 Esophageal Squamous Cell Carcinoma 1 Breast Neoplasm Female 1 Breast Cancer Metastatic 1 Breast Cancer Invasive 1 Breast Cancer Female 1 Advanced Breast Cancer 1

Interventions

pembrolizumab 45 Carboplatin 38 Pemetrexed 34 Magnetic Resonance Spectroscopy 33 Specimen Handling 32 Cisplatin 25 Blood Specimen Collection 20 Paclitaxel 15 Radiosurgery 14 durvalumab 13 Radiotherapy 13 Gemcitabine 12 Bevacizumab 12 osimertinib 11 atezolizumab 11 Biopsy 11 Practice Guidelines as Topic 10 Nivolumab 10 Educational Status 9 130-nm albumin-bound paclitaxel 9 X-Rays 8 Standard of Care 8 Immunoglobulin G 8 Docetaxel 8 Surveys and Questionnaires 7 Disulfides 7 Cetuximab 7 Taxes 6 Etoposide 6 Drug Therapy 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06563999 2024-12-10

NUMER

Sun Yat-sen University

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡